[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349946-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349946-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","circulating-tumor-dnaguided-early-detection-and-minimal-residual-disease-monitoring-in-pancreatic-and-biliary-cancers-evidence-barriers-and-opportunities","Circulating tumor DNA–guided early detection and minimal residual disease monitoring in pancreatic and biliary cancers: evidence, barriers, and opportunities","","Pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTCs) have poor outcomes due to limited early-detection strategies and frequent post-surgical relapse. Liquid biopsy, especially circulating tumor DNA (ctDNA), provides a minimally invasive and highly specific approach to reshape management. This review synthesizes recent ctDNA advances for early diagnosis/screening and postoperative minimal residual disease (MRD) monitoring, covering technology evolution, key studies, and a PDAC–BTC comparison to address assay design, interpretability, and clinical implementation barriers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/circulating-tumor-dnaguided-early-detection-and-minimal-residual-disease-monitoring-in-pancreatic-and-biliary-cancers-evidence-barriers-and-opportunities/349946/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/circulating-tumor-dnaguided-early-detection-and-minimal-residual-disease-monitoring-in-pancreatic-and-biliary-cancers-evidence-barriers-and-opportunities/349946.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are early detection and postoperative monitoring critical for pancreatic and biliary cancers?","Question",{"text":63,"@type":64},"PDAC and BTCs are often diagnosed at advanced stages, and recurrence after curative-intent surgery is common due to micrometastases not visible on conventional imaging. The article emphasizes the urgent need for better tools to improve patient survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does ctDNA support early diagnosis and MRD monitoring in this review?",{"text":68,"@type":64},"The review describes liquid biopsy using ctDNA as minimally invasive and highly specific, covering ctDNA applications in two scenarios: early diagnosis/screening and postoperative minimal residual disease monitoring.",{"name":70,"@type":61,"acceptedAnswer":71},"What technical and biological barriers influence ctDNA assay design and clinical interpretation?",{"text":72,"@type":64},"The article highlights shared barriers such as low ctDNA yield and stromal desmoplasia, as well as clonal hematopoiesis, and contrasts distinct genomic landscapes between PDAC and BTCs that affect assay design and interpretability.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349946,1790145414,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Liu et al. World Journal of Surgical Oncology (2026) 24:114  \n[https://doi.org/10.1186/s12957-026-04238-1](https://doi.org/10.1186/s12957-026-04238-1)  \nWorld Journal of Surgical Oncology  \nREVIEW Open Access  \nCirculating tumor DNA–guided early detection and minimal residual disease monitoring in pancreatic and biliary cancers:  \nevidence, barriers, and opportunities  \nRuoyan Liu1, Yang Yang1, Zhuopeng Hu 1 andYu Fu 1*  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers (BTCs) are characterized by dismal prognoses, largely because effective strategies for early detection are lacking and post-surgical relapse is common. Liquid biopsy—particularly circulating tumor DNA (ctDNA) analysis—offers a minimally invasive and highly specific approach to reshape the clinical management of these malignancies. In this review, we synthesize recent advancesin ctDNA applications across two ctDNA-guided scenarios: early diagnosis/screening and postoperative minimal residual disease (MRD) monitoring. We trace the evolution of ctDNA detection technologies from digital PCR (ddPCR) to next-generation sequencing (NGS)–based tumor-informed and tumor-agnostic assays, and summarize key prospective and retrospective studies in pancreatobiliary tumors. A central feature of our article is the side-byside comparison of PDAC and BTCs, highlighting shared technical barriers—low ctDNA yield, stromal desmoplasia, clonal hematopoiesis—and their distinct genomic landscapes (PDAC: KRAS, TP53, CDKN2A, SMAD4; BTCs: IDH1/ IDH2 mutations, FGFR2 fusions, ERBB2 or BRAF alterations), which together influence assay design and clinical interpretability. Finally, we outline clinical opportunities, including serial ctDNA-based risk stratification, ctDNAinformed adjuvant escalation/de-escalation, and the integration of multi-omics data, standardized reporting, and artificial intelligence (AI)–assisted signal analysis to improve sensitivity in low-shedding tumors. This framework aligns ctDNA technology with real-world clinical decision points in pancreatic and biliary cancers.  \nKeywords CtDNA, Pancreatic cancer, Cholangiocarcinoma, Early diagnosis, Minimal residual disease  \n*Correspondence: Yu Fu [fuyu2004@jlu.edu.cn](fuyu2004@jlu.edu.cn)  \n1Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLiu et al. World Journal of Surgical Oncology (2026) 24:114  \nIntroduction  \nThe grim clinical landscape of pancreatic and biliary cancers  \nPancreatic cancer and BTCs are among the most aggressive malignancies of the digestive system, posing a formidable challenge to global public health [1–3]. According to the latest GLOBOCAN 2022 data, pancreatic cancer ranks 12th in global cancer incidence but is the 6th leading cause of cancer-related mortality, wi","cbCait0Ug88WM685","https://ap.wps.com/l/cbCait0Ug88WM685","pdf",1313878,"English","# Abstract\n# Introduction\n## The grim clinical landscape of pancreatic and biliary cancers\n## Limitations of current diagnostic and monitoring tools\n### Serum biomarkers (CA19-9)","[{\"question\":\"Why are early detection and postoperative monitoring critical for pancreatic and biliary cancers?\",\"answer\":\"PDAC and BTCs are often diagnosed at advanced stages, and recurrence after curative-intent surgery is common due to micrometastases not visible on conventional imaging. The article emphasizes the urgent need for better tools to improve patient survival.\"},{\"question\":\"How does ctDNA support early diagnosis and MRD monitoring in this review?\",\"answer\":\"The review describes liquid biopsy using ctDNA as minimally invasive and highly specific, covering ctDNA applications in two scenarios: early diagnosis/screening and postoperative minimal residual disease monitoring.\"},{\"question\":\"What technical and biological barriers influence ctDNA assay design and clinical interpretation?\",\"answer\":\"The article highlights shared barriers such as low ctDNA yield and stromal desmoplasia, as well as clonal hematopoiesis, and contrasts distinct genomic landscapes between PDAC and BTCs that affect assay design and interpretability.\"}]","Circulating tumor DNA–guided early detection and minimal residual disease monitoring in pancreatic and biliary cancers: evidence, barriers, and opportunities | PDF",1790086387,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4604cc50fa107c046498313d0fb87484.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f7a73d0ddcb834e280931a0487339d8.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a67f46ddb95675fa3751891e7378ea5d.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5452032d47735462ca1052d43ea85e73.webp",980,1306]